FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

16 letters match. Newest first.

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  3. Sanrace Biotechnology Co., Ltd.

    FDA warns Sanrace Biotechnology over CGMP failures in OTC drugs, including missing identity tests and no process validation.

    High risk
  4. Olympus Medical Systems Corporation

    FDA warns Olympus over quality-system failures across six medical device plants, including unvalidated designs and released nonconforming devices.

    High risk
  5. TCI Co., Ltd BioCosme PABP BRANCH

    FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.

    High risk
  6. Happy Farm Botanicals, Inc.

    Happy Farm Botanicals, an OTC drug maker in Hyattsville, MD, cited for skipping ingredient identity tests and stability testing, repeat violations.

    High risk
  7. Jabil Inc.

    FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.

    High risk
  8. Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd.

    Tianjin Kilo Pharmaceutical Sci-tech, a drug ingredient maker, cited for quality failures and missing listings for demecarium bromide and chlorambucil.

    High risk
  9. Woodbine Products Company Inc.

    Inspection found Woodbine Products, an Ohio OTC drug maker, failed to test incoming ingredients like glycerin and propylene glycol for identity.

    High risk
  10. Dabur India Limited

    FDA cites Dabur India for falsified records, incomplete lab data, and inadequate cleaning and process validation for over-the-counter drugs.

    High risk
  11. ABS Corporation

    ABS Corporation released out-of-specification veterinary drugs and used inadequately tested raw materials, FDA says.

    High risk
  12. AHC Products, Inc.

    AHC Products, Inc. was cited for manufacturing-rule violations and unapproved animal drugs, including AniPrin and Rot-B-Gone.

    High risk
  13. Island Kinetics, Inc. d.b.a. CoValence Laboratories

    Island Kinetics (CoValence Laboratories) made OTC acne drugs without process validation and shipped unapproved, misbranded acne products.

    High risk
  14. Harbin Jixianglong Biotech Co., Ltd.

    FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.

    High risk
  15. JW Nutritional LLC

    FDA warns JW Nutritional over serious CGMP failures in OTC drug manufacturing, including untested components and inadequate microbial limits.

    High risk
  16. Avertix Medical, Inc.

    FDA warns Avertix Medical over Guardian implantable cardiac event detector quality violations and late injury reports.

    High risk